isirv Antiviral Group
ABOUT AVG
The isirv Antiviral Group (isirv-AVG) was established as a special interest group of isirv at the time of merger in April 2011 of the former Neuraminidase Inhibitor Susceptibility Network (NISN) with isirv.
The AVG’s specific objectives are to promote understanding of the use of antivirals and other therapeutic strategies (antibodies, immunomodulators, drug combinations, etc) against respiratory virus infections. The group collates and provides up to date information and communicates expert commentary on the emergence of antiviral resistance as well as on preclinical and clinical development of potential novel/new therapeutics.
Principal activities and areas of interest of the AVG are listed under members’ interests.
AVG COMMITTEE
The AVG committee co-ordinates the various activities and represent the interests of the isirv-AVG. Its composition reflects the range of interests and activities of the AVG and is geographically representative of its membership. Committee members have responsibility for organizing particular activities of the group and collating information on particular subject areas for the website or publication, and integrating contributions from the AVG membership.
Members are elected, initially for a period of three years. The procedure and rules for electing new members to the committee are consistent with those adopted for election to the isirv Council. Additional Members may be co-opted from the general AVG membership to serve on the Executive Committee to ensure a balance of geography, gender, scientific interests and skills.
Members will participate in an Annual Committee Meeting, typically held during an AVG-sponsored meeting. Members also participate in conference calls to generate ideas for AVG meetings/workshops, to advise on publications and other initiatives for scientific exchange, as well as to promote the activities of the Group, and isirv as a whole.
Committee members:
|
|
Biomedical Advanced Research and Development Authority (BARDA), USA |
|
|
|
|
Capital Medical University, Beijing, China |
|
|
|
University of Washington, Seattle, WA, USA |
|
|
Centers for Disease Control and Prevention, Atlanta, USA. |
|
|
|
St Jude Children's Research Hospital, Memphis, USA |
|
|
|
Centers for Disease Control and Prevention, Atlanta, USA |
|
|
|
Former Director of the WHO Collaborating Centre for Reference and Research on Influenza, London, UK AVG Past-Chair |
|
|
|
University of Virginia School of Medicine, Charlottesville, USA |
|
|
|
|
Division of Microbiology and Infectious Diseases (DMID/NIAID/NIH) CHAIR |
|
|
Public Health England, London, UK |
|
|
|
University of Texas at Austin, Austin, USA |
|
|
|
Melbourne, Australia |
|
|
|
The Rega Institute, Leuven, Belgium |
|
|
|
International Center for Research in Infectious Diseases, Lyon, France Co-Chair |
|
|
|
World Health Organisation, Geneva, Switzerland |
|
|
|
Keiyu Hospital, Yokohama, Japan |
|
|
|
National Institute of Infectious Diseases, Tokyo, Japan. |
|
|
|
|
Duke University Medical Centre, Durham, NC, USA |
|
|
|
Institut Pasteur, Paris, France |
|
|
|
University of HongKong, Hongkong SAR, China |
